Псориаз, коморбидное ожирение и эффективность ингибитора ИЛ‑23 гуселькумаба на примере клинических случаев

Данные эпидемиологических исследований демонстрируют тесную связь псориаза с сопутствующими метаболическими заболеваниями, включающие ожирение, гипертоническую болезнь, сахарный диабет, дислипидемию и неалкогольную жировую болезнь печени. Наличие сопутствующих метаболических заболеваний оказывает существенное влияние навыбор и эффективность фармакологического лечения. Из-за повышенного риска развития нежелательных явлений упациентов спсориазом и коморбидностями некоторые препараты необходимо назначать с особой осторожностью, в то же время часть препаратов показывают низкую эффективность. Ингибитор ИЛ‑23 гуселькумаб может выступать лучшей терапевтической альтернативой для пациентов с псориазом и метаболическими расстройствами, включая ожирение, по сравнению с базисными противовоспалительными препаратами (таких как метотрексат, ацитретин) и другими классами биологических препаратов. У пациентов со среднетяжелым и тяжелым псориазом ингибитор ИЛ‑23 гуселькумаб показывает высокий результат лечения с достижением PASI 90 и PASI 100, независимо от ИМТ. В представленной публикации описаны наблюдения пациентов со среднетяжелым и тяжелым псориазом, коморбидностями и высокой эфффективностью генно-инженерной биологической терапии ингибитором ИЛ‑23 (гуселькумабом).

1. Kerr J.A. et al. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. The Lancet. 2025; 405 (10481): 785–812.

2. Круглова Л.С. и др. Пcориаз. М.: ГЭОТАР-медиа. 2022. 328 с. Kruglova L.S. et al. Pcoriasis. Moscow: GEOTAR-media. 2022. 328 p. (In Russ.).

3. Czarnecka A., Purzycka-Bohdan D., Zabłotna M., Bohdan M., Nowicki R.J., Szczerkowska-Dobosz A. Considerations of the Genetic Background of Obesity among Patients with Psoriasis. Genes (Basel). 2023 Feb 26; 14 (3): 594. DOI: 10.3390/genes14030594. PMID: 36980866; PMCID: PMC10048146

4. Ryan C., Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatologic clinics. 2015; 33 (1): 41–55.

5. Owczarczyk-Saczonek A. et al. Pathogenesis of psoriasis in the “omic” era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis in psoriasis. Advances in Dermatology and Allergology/ Postępy Dermatologii i Alergologii. 2020; 37 (4): 452–467.

6. Aune D. et al. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose–response meta-analysis of prospective studies. European journal of epidemiology. 2018; 33: 1163–1178.

7. Ogawa K. et al. A transethnic Mendelian randomization study identifies causality of obesity on risk of psoriasis. Journal of Investigative Dermatology. 2019; 139 (6): 1397–1400.

8. Lønnberg A.S. et al. Association of psoriasis with the risk for type 2 diabetes mellitus and obesity. JAMA dermatology. 2016; 152 (7): 761–767.

9. Shimi G. et al. The interplay between obesity, immunosenescence, and insulin resistance. Immunity & Ageing. 2024; 21 (1): 13.

10. Secchiero P. et al. Metabolic Syndrome and Psoriasis: Pivotal Roles of Chronic Inflammation and Gut Microbiota. International Journal of Molecular Sciences. 2024; 25 (15): 8098.

11. Choudhary S. et al. The association of metabolic syndrome and psoriasis: a systematic review and meta-analysis of observational study. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2020; 20 (5): 703–717.

12. Caiazzo G. et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Frontiers in immunology. 2018; 9: 1668.

13. Nast A. et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology. 2020; 34 (11): 2461–2498.

14. Bishehsari F., Voigt R.M., Keshavarzian A. Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer. Nature Reviews Endocrinology. 2020. Т. 16. № . 12. С. 731–739.

15. Gisondi P. et al. Hypochondriasis and personality traits of patients with chronic plaque psoriasis. Dermatology. 2022; 238(2): 276–282.

16. Mehta N.N. et al. IFN-γ and TNF-α synergism may provide a link between psoriasis and inflammatory atherogenesis. Scientific reports. 2017; 7 (1): 13831.

17. Rose S. et al. Characterization of immune cells in psoriatic adipose tissue. Journal of Translational Medicine. 2014; 12: 1–13.

18. Gisondi P. et al. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. British Journal of Dermatology. 2013; 168 (4): 749–755.

19. Davidovici B.B. et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. Journal of Investigative Dermatology. 2010; 130 (7):1785–1796.

20. Eder L. et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Annals of the rheumatic diseases. 2013; 72 (12): 1956–1961.

21. Brownstein M.H. Psoriasis and diabetes mellitus. Archives of Dermatology. 1966; 93 (6): 654–655.

22. Binazzi M., Calandra P., Lisi P. Statistical association between psoriasis and diabetes: further results. Archives of Dermatological Research. 1975; 254 (1): 43–48.

23. Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA dermatology. 2013; 149 (1): 84–91.

24. Gisondi P. et al. Psoriasis and the metabolic syndrome. Clinics in dermatology. 2018; 36 (1): 21–28.

25. Di Vincenzo A. et al. Insulin stimulates IL 23 expression in human adipocytes: a possible explanation for the higher prevalence of psoriasis in obesity. Diabetes, Metabolic Syndrome and Obesity. 2023. С. 1885–1893.

26. Teng M.W. L. et al. IL 12 and IL 23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nature medicine. 2015; 21 (7): 719–729.

27. Yoshiki R. et al. IL 23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL 17A-producing γδ T cells. Journal of Investigative Dermatology. 2014; 134 (7): 1912–1921.

28. Wohn C. et al. Langerinneg conventional dendritic cells produce IL 23 to drive psoriatic plaque formation in mice. Proceedings of the National Academy of Sciences. 2013; 110 (26): 10723–10728.

29. Arnold I. C. et al. CD11c+ monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL 23. Mucosal immunology. 2016; 9 (2): 352–363.

30. Piskin G. et al. In vitro and in situ expression of IL 23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. The Journal of Immunology. 2006; 176 (3): 1908–1915.

31. Kochumon S. et al. Increased adipose tissue expression of IL 23 associates with inflammatory markers in people with high LDL cholesterol. Cells. 2022; 11 (19): 3072.

32. Pirowska M. et al. The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factorα in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2018; 35(4): 360–366.

33. Sumarac-Dumanovic M. et al. Increased activity of interleukin 23/interleukin 17 proinflammatory axis in obese women. International journal of obesity. 2009; 33 (1): 151–156.

34. Singh S. et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018; 13 (5): e0195123.

35. Mourad A. et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. British Journal of Dermatology. 2019; 181 (3): 450–458.

36. Alemany M. The metabolic syndrome, a human disease. International journal of molecular sciences. 2024; 25 (4): 2251.

37. Norden A. et al. Risk of psoriasis according to body mass index: A retrospective cohort analysis. Journal of the American Academy of Dermatology. 2022; 86 (5): 1020–1026.

38. Phan C. et al. Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases. Annales de Dermatologie et de Venéréologie. Elsevier Masson, 2016; 143 (4): 264–274.

39. Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. Journal of hypertension. 2013; 31 (3): 433–443.

40. Hu M.Y., Yang Q., Zheng J. The association of psoriasis and hypertension: focusing on ant-inflammatory therapies and immunological mechanisms. Clinical and Experimental Dermatology. 2020; 45 (7): 836–840.

41. Ma C. et al. The association between psoriasis and dyslipidaemia: a systematic review. British Journal of Dermatology. 2013; 168 (3): 486–495.

42. Wu S. et al. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis & Rheumatology. 2014; 66 (2): 304–310.